Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Tesla, Inc. (TSLA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Tesla, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Tesla, Inc. trades at $393.12 (market cap $1.51T). The key difference: Tesla, Inc. is far larger — about 336.3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | TSLA | |
|---|---|---|
Market Cap | $4.49B | $1.51T |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $489.88 |
52-Week Low | $20.06 | $295.88 |
Enterprise Value | $3.69B | $1.48T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Tesla (TSLA) trades at $395.04, down 5.89% over the past 24 hours, with a neutral technical signal and mixed earnings history. The stock shows elevated valuation ratios (P/E 369.63, P/S 14.54) against declining profitability margins (net income margin 3.95% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, while Q1 2026 deliveries missed estimates amid competitive pressures.
Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include softening auto demand and high valuation. Analyst consensus price target is $429.91, implying upside, yet sentiment is cautious with 39.51% buy ratings. Investors face volatility from execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
